Loading...
OTCM
MYMX
Market cap91kUSD
May 11, Last price  
0.00USD
Name

Mymetics Corp

Chart & Performance

D1W1MN
OTCM:MYMX chart
P/E
—
P/S
26.56
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-71.20%
Revenues
3k
0.00%
0000468,44965,000150,000222,000176,00004,381,0002,399,0003,151,0001,253,000202,00075,000111,00035,0003,0003,000
Net income
-5m
L+1.59%
-2,781,000-1,424,000-1,246,000-985,000-5,624,000-6,938,000-10,186,000-11,428,000-10,539,000-6,111,0006,003,000-3,256,000-3,006,000-5,964,000-4,112,000-4,172,000-4,187,000-4,158,000-4,730,000-4,805,000
CFO
-2m
L-0.65%
00000-7,718,000-11,046,000-7,870,000-5,223,000-4,959,000-4,344,0002,968,000730,000-987,000-2,451,000-2,313,000-972,000-1,696,000-1,698,000-1,687,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent. Additionally, Mymetics works with Sanofi Pasteur Biologics, LLC to assess the immunogenicity of influenza vaccines. Founded in 1990, the company was formerly known as ICHOR Corporation, adopting its current name in July 2001, and maintains its base of operations in Epalinges, Switzerland.
URL
https://www.mymetics.com/
IPO date
Feb 10, 1995
Employees
2
Domiciled in
CH
Incorporated in
US

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT